Neuroprotective effects of Eucommia ulmoides Oliv. Bark on amyloid beta25-35-induced learning and memory impairments in mice

Neuroscience Letters

Volumn 487, Issue 1, 2011, Pages 123-127

  Kwon, Seung Hwan ^a   Lee, Ha Kyung ^a   Kim, Ji Ah ^a   Hong, Sa Ik ^a   Kim, Sun Yeou ^b   Jo, Tae Hyung ^c   Park, Young In ^d   Lee, Chong Kil ^e   Kim, Yong Bin ^c   Lee, Seok Yong ^b   Jang, Choon Gon ^a  

^a Sungkyunkwan University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Univera Inc   (South Korea)

^d Korea University   (South Korea)

^e Chungbuk National University   (South Korea)

Author keywords

Acetylcholinerase; Alzheimer's disease; Amyloid beta25 35; Eucommia ulmoides Oliv. Bark

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[25-35]; EUCOMMIA ULMOIDES EXTRACT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARK; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FRONTAL CORTEX; HIPPOCAMPUS; IC 50; IN VITRO STUDY; LATENT PERIOD; LEARNING DISORDER; MALE; MAZE TEST; MEDICINAL PLANT; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; TU CHUNG;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUCOMMIACEAE; FRONTAL LOBE; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; PEPTIDE FRAGMENTS; PHYTOTHERAPY; PLANT BARK; PLANT PREPARATIONS; REACTION TIME; SWIMMING;

EID: 78650216499     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.042     Document Type: Article

References (19)

1. Ballard C.G., Greig N.H., Guillozet-Bongaarts A.L., Enz A., Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr. Alzheimer Res. 2005, 2:307-318.
2. Behl C., Davis J., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 1992, 186:944-950.
3. Cheng D.H., Tang X.C. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol. Biochem. Behav. 1998, 60:377-386.
4. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 1986, 19:1-28.
5. Deyama T., Nishibe S., Nakazawa Y. Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacol. Sin. 2001, 22:1057-1070.
6. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
7. Jazi R., Lalonde R., Qian S., Strazielle C. Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice. Neurosci. Res. 2009, 63:106-114.
8. Kar S., Slowikowski S.P., Westaway D., Mount H.T. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J. Psychiatry Neurosci. 2004, 29:427-441.
9. Kim D.H., Kim S., Jeon S.J., Son K.H., Lee S., Yoon B.H., Cheong J.H., Ko K.H., Ryu J.H. The effects of acute and repeated oroxylin A treatments on Abeta(25-35)-induced memory impairment in mice. Neuropharmacology 2008, 55:639-647.
10. Kim H.J., Chae S.C., Lee D.K., Chromy B., Lee S.C., Park Y.C., Klein W.L., Krafft G.A., Hong S.T. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 2003, 17:118-120.
11. Kwon S.H., Kim H.C., Lee S.Y., Jang C.G. Loganin improves learning and memory impairments induced by scopolamine in mice. Eur. J. Pharmacol. 2009, 619:44-49.
12. LeDoux J.E. Emotional memory systems in the brain. Behav. Brain Res. 1993, 58:69-79.
13. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996, 706:181-193.
14. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res. 2003, 45:117-127.
15. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 1988, 94:491-495.
16. Sberna G., Saez-Valero J., Li Q.X., Czech C., Beyreuther K., Masters C.L., McLean C.A., Small D.H. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. J. Neurochem. 1998, 71:723-731.
17. Um M.Y., Ahn J.Y., Kim S., Kim M.K., Ha T.Y. Sesaminol glucosides protect beta-amyloid peptide-induced cognitive deficits in mice. Biol. Pharm. Bull. 2009, 32:1516-1520.
18. Yamada K., Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 2000, 88:93-113.
19. 2. Teratog. Carcinog. Mutagen. Suppl. 2003, 1:23-34.